Santiago Gardella

Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis

Norma C. Gutiérrez, M. Castellanos, María Luisa Martín et al. · Leukemia · 2006 · 186 citations

Medicine, Genetics, Molecular Genetics +14

Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication

Francesc Bosch, Ana Ferrer, Neus Villamor et al. · Clinical Cancer Research · 2008 · 120 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus‐associated diffuse large B‐cell lymphoma: results of a phase II trial

Josep‐María Ribera, Albert Oriol, Mireia Morgades et al. · British Journal of Haematology · 2007 · 111 citations

Medicine, Oncology, Pharmacology +15

Randomized comparison of dexamethasone combined with melphalan <i>versus</i> melphalan with prednisone in the treatment of elderly patients with multiple myeloma

JoséM. Hernández, Ramón García‐Sánz, Estíbaliz Zamarreño Golvano et al. · British Journal of Haematology · 2004 · 78 citations

Medicine, Oncology, Pharmacotherapy +8

Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients

Joan Bladé, Jesús F. San Miguel, M. Fontanillas et al. · The Hematology Journal · 2001 · 57 citations

Medicine, Hematology, Oncology +11